Its broad intended use as a diagnostic tool to aid the detection and evaluation of diseases associated with NETosis offers a substantial commercial opportunity, with Volition's estimated Total Addressable Market in Europe, for sepsis alone, amounting to almost $6.5 billion on an annualized basis. Nu.Q® NETs is the first biomarker approved to measure NETs for patient management. Through routine blood tests, Volition's simple, low cost, accessible technology can detect NETosis, predict disease severity, and monitor its progression and response to treatment. Although NETs play an important role in our immune system, excessive production can lead to tissue damage and, in severe cases, sepsis, shock, and death. NETosis is a unique form of cell death that is characterized by the release of neutrophil extracellular traps ("NETs"), composed of decondensed chromatin, that trap and kill bacteria and viral particles. To aid the detection and evaluation of diseases associated with NETosisĪUSTIN, Texas, /PRNewswire/ - VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® NETs test has been CE marked for the detection and evaluation of NETosis, enabling clinical use in more than 27 countries across Europe.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |